NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 13 June 2016 (#18)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a ***selection*** *of pre-screened, currently open health funding opportunities for which* ***South African institutions are eligible to apply****. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

Please be advised that you ***must contact the Research Grants Management Office (RGMO) Pre-Awards*** *(Dr Christa Coetsee cdevries@sun.ac.za)* ***as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date****. The NIH grant is submitted institutionally.* ***All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- **Developing a One-Stop-Shop Knowledge Platform for Local Technologies in Africa from the African Network for Drugs and Diagnostics Innovation (ANDI) seeks local technologies and technology platforms for an open and interactive platform that can directly or indirectly impact health care in Africa.**
  Application deadline: July 31, 2016

- **Applicant webinars for the trans-NIH funding announcements Dissemination and Implementation Research in Health PAR-16-238 (R01), PAR-16-236 (R21) and PAR-16-237 (R03). Fogarty is participating in PAR-16-237 (R03).**

- **Findings of Research Misconduct (NOT-OD-16-104) National Institutes of Health**

- **Notice of Changes to the Funding Opportunity Announcement PAR-15-275 "Ethical Issues in Research on HIV/AIDS and its Co-Morbidities (R21)" (NOT-AI-16-059) and PAR-15-274 (R01)" (NOT-AI-16-060)**

- **Notice of Changes to the Funding Opportunity Announcement PAR-15-327 "Ethical, Legal and Policy Issues in HIV Research with Key Populations (R21)" (NOT-AI-16-061) and PAR-15-328 (R01)" (NOT-AI-16-062)**

- **Notice of Pre-Application Webinar for RFA-CA-15-007 "Planning for Regional Centers of Research Excellence in Non-Communicable Diseases in Low and Middle Income Countries (P20)"(NOT-CA-16-046)**

- **Notice of Change to the Specific Research Objectives for PA-16-175 Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)" (NOT-CA-16-047)**

- **Notice of Correction of Expiration Date for PA-16-177 "Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21)" (NOT-CA-16-050)**

1. Biosensors in the Oral Cavity

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DE-17-004) (RFA-DE-17-005) **Type: R01 R21**

Application Due Date: October 19, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to support interdisciplinary research in development of new or adaptation of existing biosensors for noninvasive, dynamic, real-time monitoring of physiological processes in the human body, using the oral cavity as the sensing site. Biosensors developed through this FOA should be able to assess health and disease states by receiving and analyzing signals from oral fluids, oral and dental tissues, cells and microorganisms, and compounds found in or passing through the oral cavity. Additional capabilities of these biosensors may include wireless and remote communication of outputs, local processing and/or transmitting outputs to a data collection center, and communication with drug delivery devices that can dynamically dispense therapeutic compounds to tissues in accordance with immediate physiological needs of an individual.

Budget: **R01** - NIDCR intends to commit $2 million in FY 2017 to fund 4-5 awards. Application budgets are limited to $250,000 direct costs per year. The project period is limited to no more than four years. **R21 -**The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

2. Evaluating predictive methods and product performance in Healthy Adults for Pediatric Patients, Case Study: Furosemide

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-FD-16-048) **Type: U01**

Application Due Date: August 12, 2016 by 11:59 **PM Eastern Time.** Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: Earlier exploratory CDER research projects showed that dissolution and/or solubility of a poorly soluble drug (furosemide was studied as the model drug) was higher in medium containing milk and baby formula than that in standard buffer medium. This research project will explore in vivo performance of furosemide in healthy adult volunteers following oral dosing of furosemide tablets with dosing liquids (i.e. water, milk, baby formula and Ensure Plus™). The administration of dosing liquids will mimic dosing and feeding conditions in pediatric patients (two years old and younger). The study will be designed with emphasis on the absorption phase and for careful characterization of the furosemide concentration-time profiles during the first 6 hours after dosing.

Budget: FDA/CDER intends to fund up to $250,000 for fiscal year 2016 in support of this grant program. It is anticipated that up to one (1) award will be made, not to exceed $250,000 in total costs (direct plus indirect), per award. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): Year 01 = $250,000; Year 02 = $150,000. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

3. Understanding STI Co-Infection In At Risk and HIV Infected Adolescents and Young Adults

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-HD-17-011) **Type: R01**
(RFA-HD-17-012) **R21**

Application Due Date: August 17, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) invites applications to facilitate improved understanding of the interactions between HIV and STIs in the adolescent genital and gastrointestinal mucosa.

Budget: **R01** - Application budgets may not exceed $300,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 4 years. **R21** - Application budgets are not to exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

4. Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women

Letter of Intent due date: N/A **Hyperlink:** (PA-16-311) **Type: R01**
(PA-16-312) **R21**
(PA-16-313) **R03**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments. There is a need for data on pain medications used in children and pregnant women to be shared and made available to the scientific community for future studies and to encourage replication of findings and meeting the goal of further advancing research in this area.

Budget: **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. **R21** - Application budgets may not exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested for any single year. The maximum project period is 2 years. **R03** - Application budgets for up to $50,000 per year are allowed but must reflect the actual needs of the proposed project. The maximum project period is 2 years.

5. Characterization of the Adolescent Reproductive Transition

Letter of Intent due date: N/A **Hyperlink:** (PA-16-314) **Type: R01**
(PA-16-315) **R21**
(PA-16-316) **R03**

Application Due Date: Standard dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of puberty and the trajectory of sexual development. Research using new technologies and approaches is needed to fill knowledge gaps and advance understanding of normative sexual development in both males and females. It is anticipated that the findings of studies supported by this FOA will advance knowledge of puberty and the establishment of reproductive competence.

Budget: **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years. **R21** - Application budgets are not to exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested in any single year. The maximum period is 2 years. **R03** - Application budgets are limited to $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum period is 2 years

6. Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects

Letter of Intent due date: N/A **Hyperlink:** (PAR-16-323) **Type: R03**

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. In order to be eligible for this FOA, applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.

Budget: Application budgets for up to $75,000 direct costs per year are allowed but should reflect the actual needs of the proposed project. The maximum project period is two years.

7. Biophysical and Biomechanical Aspects of Embryonic Development

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-16-325) **Type: R01**
(PAR-16-324) **R21**

Application Due Date: September 19, 2016; September 19, 2017; September 19, 2018 apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The R01 encourages applications from institutions/organizations that propose to advance our knowledge in the area of the physics and mechanics of embryonic development. Applicants should propose hypothesis-driven developmental research with the prospect of gaining new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. Investigators are encouraged to explore approaches and concepts new to the area of developmental tissue mechanics, and use newly developed techniques superior to the ones currently used in the field. It should be noted that applications submitted to this R01 FOA should have sufficient preliminary data to substantiate the validity of the proposed research and feasibility of new technologies or tools. R21 is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program can explore approaches and concepts new to the area of developmental tissue mechanics, research and development of new technologies, or initial research and development of data upon which significant future research may be built. The focus of this FOA is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders.

Budget: **R01** - The budget may not exceed $500,000 Direct Costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21** - Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. The total project period may not exceed two years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

Glossary of selected acronyms:

FOA	Funding Opportunity Announcement
PA	Program Announcements *(click on "PA" to search for further funding opportunities)*
RFA	Request for Applications *(click on "RFA" to search for further funding opportunities)*

Complete Glossary and acronym list of NIH Terms

National Institutes of Health
Turning Discovery Into Health

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: cdevries@sun.ac.za